Ischemic Stroke
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age >=18 years; 2. Hospitalized within 6 months of onset, with ischemic stroke confirmed by Magnetic Resonance Imaging (MRI), and the stroke etiology clearly defined as non-cardioembolic according to the TOAST classification; 3. Currently receiving monotherapy antiplatelet treatment (either Aspirin or Cilostazol) at the time of enrollment; 4. Underwent Susceptibility-Weighted Imaging (SWI) during hospitalization, and the presence of at least one Cerebral Microbleed (CMB) was confirmed.
Exclusion criteria
Exclusion criteria: 1. Stroke etiology is cardioembolic; 2. Patients who continuously received dual antiplatelet therapy, any form of anticoagulation therapy, or no antiplatelet medication at all within 6 months prior to enrollment; 3. History of severe adverse reactions to Aspirin or Cilostazol (such as active bleeding, severe allergy, etc.), leading to inability to comply with the medication regimen; 4. Patients with severe comorbidities, specifically including: severe hepatic insufficiency (defined as Child-Pugh Class B or C), renal failure (defined as estimated Glomerular Filtration Rate (eGFR)<30ml/min/1.73m2),evere heart failure [NYHA Class III-IV], or history of active malignant tumor; 5. Patients with a definite or probable diagnosis of Cerebral Amyloid Angiopathy (CAA) based on the Boston 2.0diagnostic criteria; 6. Severe missing key baseline or follow-up data that prevents effective evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| any stroke;intracranial hemorrhage during follow-up; | — |
Secondary
| Measure | Time frame |
|---|---|
| ischemic stroke;non-bleeding adverse events;myocardial infarction;all-cause death;other bleeding events;composite endpoint of major adverse cardiovascular and cerebrovascular events;vascular death; | — |
Countries
China
Contacts
Zhejiang Provincial People's Hospital